What's in Grünenthal GmbH's pipeline?

Grünenthal GmbH has 31 drugs in our index: 4 marketed, 0 filed, 14 in Phase 3, 1 in Phase 2, 12 in Phase 1.

Which companies overlap with Grünenthal GmbH's portfolio?

Top competitors by shared drug class: London School of Hygiene and Tropical Medicine, Purdue Pharma LP, Bayer, GlaxoSmithKline, Mundipharma Research GmbH & Co KG.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/gr-nenthal-gmbh.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Grünenthal GmbH — Portfolio Competitive Intelligence Brief

Grünenthal GmbH pipeline: 4 marketed, 0 filed, 14 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4 marketed 0 filed 14 Phase 3 1 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Topical analgesic	Topical analgesic	marketed	Topical analgesic		Pain Management
Oxycodone/Naloxone Prolonged Release	Oxycodone/Naloxone Prolonged Release	marketed	Opioid analgesic with abuse-deterrent formulation	Mu-opioid receptor (oxycodone); opioid receptors (naloxone antagonism)	Pain Management
Tapentadol Prolonged Release with Pregabalin	Tapentadol Prolonged Release with Pregabalin	marketed
Tapentadol Prolonged Release	Tapentadol Prolonged Release	marketed	Mu-opioid receptor agonist and noradrenaline reuptake inhibitor	Mu-opioid receptor; noradrenaline transporter (NET)	Pain Management
Matching Placebo (twice daily)	Matching Placebo (twice daily)	phase 3
CG5503 IR	CG5503 IR	phase 3	TRPV1 antagonist	TRPV1 (Transient Receptor Potential Vanilloid 1)	Pain Management
Clarithromycin DST (187.5 mg)	Clarithromycin DST (187.5 mg)	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit	Infectious Disease
Clarithromycin Syrup (125 mg)	Clarithromycin Syrup (125 mg)	phase 3	Macrolide antibiotic	Bacterial 50S ribosomal subunit	Infectious Disease
Tramadol/Diclofenac 25/25	Tramadol/Diclofenac 25/25	phase 3	Opioid analgesic/NSAID	Opioid receptors/COX enzymes	Pain management
Morphine Sulphate Controlled Release	Morphine Sulphate Controlled Release	phase 3	Opioid analgesic	Mu opioid receptor (OPRM1)	Pain Management
Placebo Plaster	Placebo Plaster	phase 3
Tramadol/Diclofenac 50/50	Tramadol/Diclofenac 50/50	phase 3	Opioid analgesic/NSAID	Opioid receptors/COX enzymes	Pain management

Therapeutic area mix

Pain Management · 7
Infectious Disease · 4
Pain management · 3
Pain · 1
Pain Management, Rheumatology, Inflammation · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

London School of Hygiene and Tropical Medicine · 2 shared drug classes
Purdue Pharma LP · 2 shared drug classes
Bayer · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Mundipharma Research GmbH & Co KG · 2 shared drug classes
Pfizer · 2 shared drug classes
Abbott · 2 shared drug classes
Teva Branded Pharmaceutical Products R&D, Inc. · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Grünenthal GmbH:

Cite this brief

Drug Landscape (2026). Grünenthal GmbH — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/gr-nenthal-gmbh. Accessed 2026-05-16.